Market closed
ProKidney Corp./$PROK
ProKidney shares are trading higher after the company reported its Q1 results.
5 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Ticker
$PROK
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
204
ISIN
KYG7S53R1049
Website
ProKidney Corp. Metrics
BasicAdvanced
$100M
-
-$0.60
1.58
-
Price and volume
Market cap
$100M
Beta
1.58
52-week high
$1.34
52-week low
$0.46
Average daily volume
1.1M
Financial strength
Current ratio
10.963
Quick ratio
10.066
Long term debt to equity
0.679
Total debt to equity
0.911
Interest coverage (TTM)
-25,666.29%
Management effectiveness
Return on assets (TTM)
-28.29%
Return on equity (TTM)
-45.28%
Valuation
Price to revenue (TTM)
289.669
Price to book
-0.1
Price to tangible book (TTM)
-0.1
Price to free cash flow (TTM)
-0.587
Growth
Earnings per share change (TTM)
3.86%
3-year earnings per share growth (CAGR)
-3.65%
ProKidney Corp. News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ProKidney Corp. stock?
ProKidney Corp. (PROK) has a market cap of $100M as of May 16, 2025.
What is the P/E ratio for ProKidney Corp. stock?
The price to earnings (P/E) ratio for ProKidney Corp. (PROK) stock is 0 as of May 16, 2025.
Does ProKidney Corp. stock pay dividends?
No, ProKidney Corp. (PROK) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next ProKidney Corp. dividend payment date?
ProKidney Corp. (PROK) stock does not pay dividends to its shareholders.
What is the beta indicator for ProKidney Corp.?
ProKidney Corp. (PROK) has a beta rating of 1.58. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.